Form 4: GoodRx Director Ronald Bruehlman Receives Stock Units
Statement of Changes in Beneficial Ownership
Director Ronald E. Bruehlman was granted 4,642 deferred stock units as part of his compensation package with GoodRx Holdings, Inc.
Summary
- Director Ronald E. Bruehlman acquired 4,642 deferred stock units (DSUs) on May 27, 2026.
- Each DSU represents a contingent right to receive one share of Class A common stock.
- The units vest 2% on May 31, 2026, with the remaining 98% vesting in equal monthly installments over the following 7 months.
- Following this transaction, the director's total beneficial ownership is 133,918 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.
Positives
- The grant aligns director compensation with long-term shareholder interests through equity-based incentives.
Negatives
- None identified; this is a standard compensatory equity grant for a board member.
Risks
- Vesting is subject to the director's continued service through the applicable dates.
Future Outlook
The deferred stock units will settle upon the earliest of December 31, 2031, separation from service, a change in control, death, or disability.
Management Comments
- No direct management commentary provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the healthcare technology sector to ensure alignment between governance and shareholder value.
Comparison to Industry Standards
- The grant structure is consistent with standard corporate governance practices for publicly traded companies in the U.S.
- The use of deferred stock units is a common mechanism for director compensation to defer tax liabilities and maintain long-term commitment.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity compensation grant.
Next Steps
- Vesting of 2% of the units on May 31, 2026.
- Monthly vesting of the remaining 98% over the subsequent 7 months.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Date of the earliest transaction involving deferred stock units. |
| 05/29/2026 | Date the Form 4 was filed with the SEC. |
| 05/31/2026 | Initial vesting date for 2% of the granted deferred stock units. |
Keywords
GoodRx, GDRX, Form 4, Insider Trading, Director Compensation, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.